Literature DB >> 10468523

Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS (GISCA).

G Barbaro1, G Di Lorenzo, M Soldini, G Giancaspro, B Grisorio, A Pellicelli, G Barbarini.   

Abstract

BACKGROUND: Increased levels of tumor necrosis factor-alpha (TNF-alpha) and inducible nitric oxide synthase (iNOS) have been reported in patients with dilated cardiomyopathy. We investigated the myocardial expression of TNF-alpha and iNOS in patients with HIV-associated cardiomyopathy (HIV-DCM) compared with patients with idiopathic dilated cardiomyopathy (IDCM). METHODS AND
RESULTS: Endomyocardial biopsy specimens from 82 HIV-DCM and 80 IDCM patients were processed for determination of the immunostaining intensity of TNF-alpha and iNOS and for virological examination. Negative controls were derived from autopsy myocardium specimens from 32 HIV-negative patients without known heart disease. The mortality rate for congestive heart failure between groups according to the intensity of iNOS staining was also evaluated. The mean intensity of both TNF-alpha and iNOS staining was greater in patients with HIV-DCM (0.81 and 1.007, respectively) than in patients with IDCM (0.44 and 0.49, respectively) and controls (0.025 and 0.027, respectively). The staining intensity of both TNF-alpha and iNOS was inversely correlated with CD4 count. The staining intensity of iNOS was greater in HIV-DCM patients with HIV/coxsackievirus B3 (CVB3) or with HIV/cytomegalovirus coinfection than in IDCM patients showing infection with CVB3 and adenovirus alone. The staining intensity of iNOS correlated to mortality rate, because it was higher in HIV-DCM patients and, in particular, in those with an optical density unit >1.
CONCLUSIONS: Cytokine activation seems to play a significant pathogenetic role in both HIV-DCM and IDCM. In HIV-DCM patients, the state of immunodeficiency may favor the selection of viral variants of increased pathogenicity, influencing the clinical course of cardiomyopathy by enhancement of the inflammatory process.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10468523     DOI: 10.1161/01.cir.100.9.933

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  16 in total

Review 1.  Cardiovascular manifestations of HIV infection.

Authors:  G Barbaro
Journal:  J R Soc Med       Date:  2001-08       Impact factor: 5.344

Review 2.  Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine development.

Authors:  Sheila M Keating; Evan S Jacobs; Philip J Norris
Journal:  Cytokine Growth Factor Rev       Date:  2012-06-27       Impact factor: 7.638

Review 3.  Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy.

Authors:  B Maisch; S Pankuweit
Journal:  Herz       Date:  2012-09       Impact factor: 1.443

4.  Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion- and death receptor-controlled pathways.

Authors:  Cheryl Twu; Nancy Q Liu; Waldemar Popik; Michael Bukrinsky; James Sayre; Jaclyn Roberts; Shammas Rania; Vishnu Bramhandam; Kenneth P Roos; W Robb MacLellan; Milan Fiala
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-11       Impact factor: 11.205

Review 5.  Heart failure in patients with human immunodeficiency virus infection: epidemiology, pathophysiology, treatment, and future research.

Authors:  Joshua Remick; Vasiliki Georgiopoulou; Catherine Marti; Igho Ofotokun; Andreas Kalogeropoulos; William Lewis; Javed Butler
Journal:  Circulation       Date:  2014-04-29       Impact factor: 29.690

Review 6.  Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives.

Authors:  Bernhard Maisch; Sabine Pankuweit
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

7.  Isothiocyanates ameliorate the symptom of heart dysfunction and mortality in a murine AIDS model by inhibiting apoptosis in the left ventricle.

Authors:  Jin-Nyoung Ho; Ho-Geun Yoon; Chang-Soo Park; Sunoh Kim; Woojin Jun; Ryowon Choue; Jeongmin Lee
Journal:  J Med Food       Date:  2012-09       Impact factor: 2.786

8.  Mitochondrial dysfunction in human immunodeficiency virus-1 transgenic mouse cardiac myocytes.

Authors:  Joseph Y Cheung; Jennifer Gordon; JuFang Wang; Jianliang Song; Xue-Qian Zhang; Fabian Jana Prado; Santhanam Shanmughapriya; Sudarsan Rajan; Dhanendra Tomar; Farzaneh G Tahrir; Manish K Gupta; Tijana Knezevic; Nana Merabova; Christopher D Kontos; Joseph M McClung; Paul E Klotman; Muniswamy Madesh; Kamel Khalili; Arthur M Feldman
Journal:  J Cell Physiol       Date:  2018-09-07       Impact factor: 6.384

Review 9.  Myocardial disease in human immunodeficiency virus (HIV) infection: a review.

Authors:  Mahmoud Umar Sani
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 10.  Risk Factors for the Development of Atrial Fibrillation in HIV Infected Patients.

Authors:  Yaser Elnahar; Joseph Daoko; Anthony Al-Dehneh; Nishant Gupta; Vincent A DeBari; Fayez Shamoon; Constantinos A Costeas
Journal:  J Atr Fibrillation       Date:  2012-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.